Avdoralimab (IPH5401)
Not specified (C5aR target)
Phase 1/2Status unclear
Key Facts
About Innate Pharma
Founded in 1999 by pioneering immunologists, Innate Pharma is a Nasdaq and Euronext-listed biotech focused on harnessing the innate immune system to fight cancer. The company has built a robust pipeline of proprietary and partnered assets, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4 ADC), and monalizumab (anti-NKG2A, partnered with AstraZeneca). Its strategy is underpinned by strong scientific foundations, strategic collaborations with major players like AstraZeneca and Sanofi, and a leadership team with deep industry and scientific expertise.
View full company profile